Company ProfilePremium

B2B Software Technologies Limited

Company Profile Analysis

Ticker: 531268.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
B2B Software Technologies Limited - Company showcase

Year Founded & Workforce

1994

106 Employees

B2B Software Technologies Limited logo

B2B Software Technologies Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

B2B Software Technologies Limited Overview

B2B Software Technologies is a Hyderabad-based micro-cap IT services company with roughly 30 years of history. Its core business is implementing, customising and supporting Microsoft Dynamics enterprise resource planning (ERP) and customer relationship management (CRM) systems for small and mid-sized organisations. Its legacy Dynamics competencies were NAV and AX; it now works on Dynamics 365 Business Central. On top of that services core it sells proprietary Microsoft-certified add-on modules: HR & Payroll, Quality Control, Plant Maintenance, and B2B LIFT for life sciences. It also operates GeniusDoc, a medical-practice management system serving the US market through its wholly owned subsidiary, B2B Softech Inc. In August 2025 it launched an "Emerging Technologies" division covering AI, machine learning, large language models (LLMs), agentic chatbots, robotic process automation (RPA), blockchain, cloud migration and cybersecurity. That launch was anchored by a USD 1 million, five-year AI contract with a US oncology practice, which is a related party. FY2026 consolidated revenue was INR 30.46 Cr (+26.2%). The company has no debt, is profitable, paid its first dividend in FY2026, and is promoter-controlled (56.5%).


What the company does. The company has three revenue engines. First, Microsoft Dynamics ERP/CRM implementation and support: business-process analysis, system design, implementation, data migration, training, user acceptance testing (UAT), go-live, hypercare and annual maintenance. Second, proprietary add-on software built on the Dynamics platforms and sold to Dynamics customers, including through other resellers. Screener's AI extraction of the annual report tracks an "add-on sales through resellers" KPI. Third, healthcare IT in the US through the GeniusDoc practice-management/EMR product and, since FY2026, AI and data services for an oncology practice. The company describes itself as a business-solution implementation company in the Microsoft Dynamics space. It offers offshore and onsite solution development for mid-to-large enterprises (Screener summary of the FY2025 annual report).

The company's own description. The company's long-standing self-description is that it is a Microsoft Gold ERP partner and a leading business-solution implementation company in the Microsoft Dynamics space. It specialises in business process analysis, system design, technical expertise, implementation, training and support. Its FY2025 Directors' Report adds the launch of the Emerging Technologies division and describes Microsoft Dynamics CRM and ERP as software that connects people, processes and systems.

Independent characterisation. This is best viewed as a sub-scale, people-intensive Microsoft channel services firm. Employee cost absorbed 62.8% of FY2026 revenue. It has a thin intellectual-property overlay (the add-ons and GeniusDoc) and a small US healthcare foothold that is now driving most incremental growth. The "Gold Certified" label refers to Microsoft's legacy competency framework. Microsoft replaced Gold/Silver competencies with "Solutions Partner" designations under the Microsoft Cloud Partner Program in 2022. The company's current designation is not publicly disclosed in sources reviewed.

Revenue model mix. The company does not disclose a split of product, service, subscription and licence revenue. Disclosed contracts indicate the following mix:

Value-chain position. The company is a downstream system integrator and independent software vendor (ISV) within the Microsoft ecosystem. It depends on Microsoft's product roadmap, licensing and partner-program economics. It does not own a platform.

Customer types and end-markets. The company targets small and mid-sized manufacturers and life-sciences firms: pharmaceutical, biotech, food processing and chemicals, per its LIFT product positioning. Other targets are agribusiness (Kongoni River Farm in Kenya and Ethiopia), US physician practices and oncology centres, and telecoms (named in a PitchBook description). Geographically it serves India, the USA and, more recently, East Africa. It does not disclose a customer count.

Strategy

Stated strategy themes. These are paraphrased from the FY2025 Directors' Report and Regulation 30 disclosures. The company does not hold investor days.

  1. Move up the value chain from ERP implementation into emerging technologies. The company has positioned the Emerging Technologies division as its response to rapidly growing demand for innovative and transformative solutions.

  2. Leverage the Microsoft Dynamics core. It continues to sell implementation, add-ons and AMC on Business Central and D365, with AI layered on top (the website markets "Microsoft Dynamics 365 AI" and AI agents).

  3. Vertical healthcare focus in the US. It pairs GeniusDoc with AI and ML for oncology workflows.

  4. Employee alignment. It uses ESOP and RSU schemes to retain talent.

  5. Shareholder-return and liquidity initiatives. These include the first dividend, a bonus issue and a proposed stock split.

Strategic initiatives register (last 24 months):

Sustainability / ESG commitments: none disclosed. Cost programmes: none disclosed.

Medium-term financial targets / guidance: none publicly issued. The company does not provide guidance.

Products & Services

A. Microsoft Dynamics services (core)

B. Proprietary add-on IP (Microsoft-certified, built on Dynamics)

C. Healthcare IT (primarily US, via B2B Softech Inc.)

D. Emerging Technologies Division (launched August–September 2025)

Pricing, flagship SKUs and launch versions for the Emerging Technologies offerings are not publicly disclosed. Initial investment was INR 1.00 Cr of capex from internal accruals.

Product Portfolio

OfferingDescription / capabilitiesTarget customerVersion / yearPricing model

Microsoft Dynamics NAV implementation

ERP for small and mid-size organisations covering finance, supply chain and operations

Small and mid-sized manufacturers and distributors

Legacy platform; NAV has been superseded by Business Central

Project fees plus annual maintenance contract (AMC); not disclosed

Microsoft Dynamics AX / D365 Finance & Operations

Larger-enterprise ERP implementation, upgrade and maintenance

Mid-to-large enterprises

AX legacy; D365 F&O current (company website references NAV, AX and AI)

—

Dynamics 365 Business Central

Cloud ERP implementation, data migration, training, UAT, go-live, hypercare, AMC

Small and mid-sized businesses incl. agribusiness (Kenya and Ethiopia)

Current; June 2026 order

Milestone-based project fee plus 500 support hours a year (Learnovate order)

Microsoft Dynamics CRM

CRM implementation

Mid-market

Listed since at least 2009

—

Consulting, customisation, cloud migration, support

Business-process analysis, system design, custom development, cloud migration

Existing Dynamics users

Ongoing

Time-and-materials (inferred)

“—” = not publicly disclosed.

ProductDescriptionTarget customerPlatformPricing

B2B HR & Payroll

Salary computation, leave and attendance management. Positioned as covering the employee lifecycle from recruitment to exit

Indian and international mid-market employers

NAV / Business Central (implied)

Licence; not disclosed

B2B Quality Control (NAV & AX)

Integrates quality checks into supply-chain, manufacturing and inventory processes

Manufacturers, regulated industries

NAV and AX

Licence; not disclosed

B2B Plant Maintenance (NAV)

Plant/equipment maintenance management within ERP

Process and discrete manufacturers

NAV

Licence; not disclosed

B2B LIFT

Life-sciences ERP vertical (pharma, biotech, food processing, chemicals)

Life-sciences companies

NAV

Licence; not disclosed

PO Automation add-on

Purchase-order automation

Business Central users

Business Central

Licences sold per country (Kenya and Ethiopia) under the June 2026 order

Product / serviceDescriptionTarget customerNotes

GeniusDoc

Medical-practitioner / physician practice management system (EMR heritage dating to 2009 listings)

US physician practices

The AGM resolution approved related-party transactions with Antelope Valley Cancer Center "in collaboration with Genius doc"

Oncology AI program (Antelope Valley Cancer Center)

AI, ML, deep learning, agentic chatbots, data mining, digital workflow transformation and enhanced cybersecurity to improve efficiency, quality of care and operations

US oncology practice (related party)

USD 1,000,000 over 60 months (disclosed 13 August 2025)

Practice areaStated scope

AI / ML / LLM

Model development, LLM integration

Agentic chatbots

Conversational and agentic automation; company website now markets "B2B AI Solutions" including AI agents and Dynamics 365 AI

Blockchain

Blockchain technologies (no named offering)

RPA and digital workflow transformation

Process automation

Data mining, warehousing, advanced analytics

Data platforms

Low-code / no-code tools

Application development

Cloud migration

Infrastructure modernisation

Cybersecurity

Security services

Financial Narrative

Source: Screener.in consolidated data (C-MOTS feed from BSE filings) for FY2022–FY2026; employee cost from Research360; margins and ratios computed by the analyst unless noted. All figures are INR Cr unless stated.

Income statement

Notes on the income statement:

Gross profit: is not reported. Indian IT services filers present costs by nature, not cost of sales. Simply Wall St's own construction shows trailing-twelve-month gross profit of INR 8.65 Cr on INR 29.91 Cr revenue (to December 2025), a gross margin of about 28.9%. That is a third-party definition, not a company disclosure.

Diluted EPS: is not separately disclosed in accessible sources. The ESOP options outstanding (250,325 plus 24,811) are small against 17.38 million shares.

Revenue CAGR: FY2021–FY2026 (5-year) is 15.4%; FY2022–FY2026 (4-year) is 11.2%. Net income CAGR: FY2021–FY2026 is 8.6%; FY2022–FY2026 is 1.5%.

Margin profile

Commentary. The five-year record has three phases.

  1. FY2022 peak. Revenue jumped 33.6% and operating margin reached 15.5%. That was the post-pandemic demand surge for cloud ERP in the mid-market.

  2. FY2023–FY2024 compression. Revenue was flat at about INR 20 Cr while employee cost rose about 14% over the two years. Operating margin collapsed to 6.0%. In FY2024, other income (treasury yield on about INR 14 Cr of investments) contributed 56% of pre-tax profit. In that year the business was effectively an investment portfolio with a small services operation attached.

  3. FY2025–FY2026 re-acceleration. Revenue grew 18.8% and then 26.2%, driven predominantly by the US subsidiary. Operating margin recovered only partially, to about 8%, because headcount cost grew in step: employee cost rose 26.5% in FY2025 and 22.4% in FY2026.

The structural conclusion is that growth has not yet produced operating leverage. Other income still contributes more than a third of pre-tax profit. Quarterly operating margin has swung between 3.5% and 15.0% over the last five quarters, which shows high sensitivity to project timing.

Quarterly trajectory (consolidated, INR Cr)

Q1 FY27 (latest quarter). Revenue was INR 7.39 Cr (+14.2% year-on-year, –8.1% quarter-on-quarter). Operating margin was 7.04% versus 4.33% a year earlier. Net income was INR 0.92 Cr (+41.5%). However, other income of INR 0.73 Cr equalled 60% of pre-tax income. The year-on-year profit improvement is therefore of mixed quality. Standalone Q1 FY27 revenue was INR 3.65 Cr (+14.4%) with net income of INR 0.63 Cr (+6.8%).

Balance sheet

Notes on the balance sheet:

Equity capital: rose to about INR 17.38 Cr after the April 2026 bonus, with an offsetting reduction in reserves of INR 5.79 Cr.

  • Cash and equivalents, goodwill/intangibles and working capital are not separately disclosed in accessible sources. Goodwill is presumed nil or immaterial because there have been no acquisitions.

Net debt: is negative (net cash). The company has zero borrowings and INR 18.01 Cr of investments. The liquidity of the investment book (fixed deposits, mutual funds or other) is not disclosed.

Commentary. The balance sheet is pristine but capital-inefficient. About 64% of assets sit in investments against an operating business that needs well under INR 1 Cr of fixed assets. Equity has compounded at about 12% a year purely through retained earnings, and FY2026 was the first year any capital was returned. The INR 18 Cr investment book equals about 48% of the current market capitalisation.

Cash flow

Two points on these figures. Dividends paid are inferred from the financing outflow, which matches INR 1 per share on about 11.59 million pre-bonus shares. FY2026 operating cash flow more than doubled, helped by a fall in debtor days to 13.

Return, leverage and efficiency ratios

How the derived ratios were built and what could not be computed:

Operating ROIC: equals EBIT × (1 – tax rate) divided by year-end (equity – investments). It is analyst-derived.

Current ratio: is not disclosed; the liquidity proxy above stands in for it.

Interest coverage: and net debt/EBITDA are not meaningful because finance cost and debt are zero.

Commentary. Headline ROE of about 12% understates the economics of the operating business. Stripping out the low-yield investment book, operating capital earns about 25% after tax. The value question is therefore capital allocation, not business quality per se.

The rising "inventory days" (8.9 to 32.6) is unusual for a services company. It likely reflects licence stock or unbilled work-in-progress, but the company has not explained it. Rising inventory days combined with collapsing payable days have lengthened the cash conversion cycle from 13 to 42 days, even as debtor days improved.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipFunctionStatus

B2B Software Technologies Ltd (India)

Listed parent

Dynamics implementation, add-on IP, offshore delivery, Emerging Technologies division

Active

B2B Softech Inc. (USA)

100%

US sales and delivery; healthcare IT (GeniusDoc)

Active; sole subsidiary at 31 March 2025

B2B ESOP Trust

Controlled trust

Holds 600,000 shares for ESOP/RSU

Active

Emerging Technologies Division

Internal division

AI, ML, LLMs, agentic chatbots, RPA, blockchain, low-code, cloud migration, cybersecurity

Operations from September 2025

Revenue by Segment and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025FY2026

Consolidated revenue (INR Cr)

19.9119.7720.3224.1430.46

Standalone parent revenue (INR Cr)

14.5513.4013.9215.1416.07

Derived subsidiary revenue (INR Cr)

5.366.376.409.0014.39

Standalone share of consolidated (%)

73.167.868.562.752.8

Derived subsidiary share of consolidated (%)

26.932.231.537.347.2

Standalone revenue growth YoY (%)

0-7.93.98.86.1

Derived subsidiary revenue growth YoY (%)

018.80.540.659.9

Consolidated net profit (INR Cr)

2.672.381.852.632.84

Standalone net profit (INR Cr)

2.502.271.722.402.30

Derived subsidiary net profit (INR Cr)

0.170.110.130.230.54

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

19.9119.7720.3224.1430.46

Revenue growth YoY (%)

33.6-0.72.818.826.2

Employee cost (INR Cr)

10.8211.3612.3515.6219.12

Total operating expenses (INR Cr)

16.8317.7219.1022.2127.93

EBITDA excl. other income (INR Cr)

3.082.051.221.932.53

Other income (INR Cr)

0.570.751.341.461.44

PBDT, i.e. EBITDA incl. other income (INR Cr)

3.652.802.563.393.97

Depreciation (INR Cr)

0.070.110.170.130.13

Operating income, EBIT excl. other income (INR Cr)

3.011.941.051.802.40

Finance cost (INR Cr)

00000

Pre-tax income (INR Cr)

3.582.692.393.263.84

Effective tax rate (%)

25.1411.1523.0119.3325.78

Net income (INR Cr)

2.672.381.852.632.84

EPS basic, bonus-adjusted (INR)

1.531.371.061.511.63

EPS on pre-bonus share base, derived (INR)

2.302.051.602.272.45

Dividend per share, pre-bonus base (INR)

00001

Dividend payout (%)

000040.81

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin excl. other income (%)

15.4710.376.008.008.31

EBITDA margin incl. other income (%)

18.314.212.614.013.0

Operating (EBIT) margin (%)

15.19.85.27.57.9

Net margin (%)

13.412.09.110.99.3

Employee cost as % of revenue (%)

54.357.560.864.762.8

Other income as % of pre-tax income (%)

15.927.956.144.837.5

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (INR Cr)

5.036.225.407.486.477.668.288.047.39

Operating profit (INR Cr)

0.830.310.370.400.280.701.240.280.52

Operating margin (%)

16.504.986.855.354.339.1414.983.487.04

Other income (INR Cr)

0.370.410.360.350.600.250.460.160.73

Pre-tax income (INR Cr)

1.170.690.700.720.850.921.670.401.21

Net income (INR Cr)

1.120.310.650.560.650.631.240.320.92

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

11.5911.5911.5911.5911.59

Reserves (INR Cr)

4.236.578.4310.8813.54

Total equity (INR Cr)

15.8218.1620.0222.4725.13

Gross borrowings (INR Cr)

00000

Other liabilities (INR Cr)

1.961.882.802.923.10

Total assets (INR Cr)

17.7820.0422.8225.3928.23

Net fixed assets (INR Cr)

0.120.370.310.230.28

Investments (INR Cr)

11.1913.1013.8816.4918.01

Other assets incl. receivables and cash (INR Cr)

6.476.578.638.679.94

Book value per share, bonus-adjusted (INR)

9.1010.4511.5212.9314.46

Investments as % of total assets (%)

62.965.460.864.963.8

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

2.041.841.491.573.31

Capex, derived (INR Cr)

0.050.330.100.060.18

Free cash flow (INR Cr)

1.991.511.391.513.13

Investing cash flow (INR Cr)

-0.95-1.540.10-1.680.35

Financing cash flow (INR Cr)

0000-1.16

Dividends paid, inferred (INR Cr)

00001.16

Share buybacks (INR Cr)

00000

Net change in cash (INR Cr)

1.090.301.59-0.112.51

FCF as % of net income (%)

74.563.475.157.4110.2

Operating cash flow before tax / EBITDA, per Screener (%)

669012281131

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

18.714.09.712.411.9

ROA on average assets (%)

16.312.68.610.910.6

ROCE, per Screener (%)

25.0615.6011.3115.2015.84

Operating ROIC excl. treasury investments, derived (%)

48.634.113.224.325.0

Debt to equity (x)

00000

Liquidity proxy: (investments + other assets) / other liabilities (x)

9.010.58.08.69.0

Asset turnover (x)

1.221.050.951.001.14

Debtor days

29.3322.1533.4123.1313.06

Inventory days

8.8812.3917.0623.6332.59

Days payable

25.526.7629.561.313.26

Cash conversion cycle (days)

12.6927.7920.9045.4542.39

Revenue by Region and Region Margins & Growth (%)

Region (proxy)FY2024FY2025FY2026

India-entity revenue, standalone (INR Cr)

13.9215.1416.07

USA-subsidiary revenue, derived (INR Cr)

6.409.0014.39

India-entity growth YoY (%)

3.98.86.1

USA-subsidiary growth YoY (%)

0.540.659.9

USA-subsidiary share of total (%)

31.537.347.2

Valuation Snapshot

MetricValueDate / source

Last close

INR 21.40

19 October 2026 (Screener)

Market capitalisation

INR 37.2 Cr

19 October 2026 (Screener)

52-week high / low

INR 38.00 / INR 15.81. The high was recorded 9 February 2026 and the low 14 January 2026; the mix of bonus-adjusted and unadjusted prices across sources is unclear

Accord Fintech; Screener

1-year return

–1% (Screener CAGR) / +3.62% (ScanX); timing differences

October 2026

3-year price CAGR

3%

Screener

5-year price CAGR

1%

Screener

10-year price CAGR

11%

Screener

6-month return

–30.58%

ScanX, October 2026

Shareholders

9,017

September 2026

Share Price & Returns

DateClose (INR)Basis

21 Nov 2024

37.14

Pre-bonus

13 Aug 2025

32.68 (intraday)

Pre-bonus

21 Dec 2025

29.40

Pre-bonus

16 Jan 2026

24.85

Pre-bonus

3 Jun 2026

24.44

Post-bonus

22 Jul 2026

27.70

Post-bonus

9 Oct 2026

21.61

Post-bonus

19 Oct 2026

21.40

Post-bonus

Valuation Multiples

MultipleB2B SoftwareBasis

P/E (trailing twelve months)

12.0x

Screener; TTM net income INR 3.11 Cr

P/B

1.48x

Price INR 21.4 / book value INR 14.4

EV/Sales (TTM)

0.61x

EV of about INR 19.2 Cr (market cap 37.2 less investments 18.01) / TTM revenue INR 31.37 Cr

EV/EBITDA excl. other income (TTM)

7.0x

EV of about INR 19.2 Cr / TTM operating profit INR 2.74 Cr

Dividend yield

3.11%

Screener (INR 1 pre-bonus, about INR 0.67 post-bonus equivalent)

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share, pre-bonus base (INR)

00001

Dividends paid (INR Cr)

00001.16

Payout ratio (%)

000040.81

Capital Markets

ItemStatus

Credit ratings (Moody's, S&P, Fitch, CRISIL, ICRA, CARE, India Ratings)

None. The company is unrated and has no rated debt

Debt maturity profile

Not applicable: zero borrowings

Analyst Conclusions

Management guidance: none issued. Consensus expectations: none (no coverage).

Run-rate indicators. Q1 FY27 revenue of INR 7.39 Cr annualises to about INR 29.6 Cr, roughly flat against FY2026's INR 30.46 Cr. Adding the Learnovate order (about INR 1.4 Cr over 6–8 months) and continued Antelope Valley billing (about INR 1.7 Cr a year) points to FY2027 revenue in the INR 30–34 Cr range absent new wins. This is an analyst scenario, not guidance.

Bull case:

  1. Hidden operating value. At an EV of about INR 19 Cr and EV/EBITDA of 7x on a business with operating ROIC of about 25% that is growing revenue in double digits (FY2025 +18.8%, FY2026 +26.2%, Q1 FY27 +14.2%), the core is cheap if growth persists.

  2. Capital-allocation inflection. The first dividend (40.8% payout), the bonus, a pending split and an INR 18 Cr investment book give room for higher payouts or a buyback that would re-rate the stock.

  3. AI and healthcare optionality. If the oncology AI program can be replicated with non-related US practices, the US subsidiary already at about 47% of revenue could keep compounding at 40–60%.

Bear case:

  1. Growth quality. About 88% of FY2026 incremental revenue came through the US subsidiary at an implied net margin of about 3.8%. Consolidated net income rose only 8% on 26% revenue growth.

  2. Governance overhang. The anchor AI contract is a related-party transaction. The promoter stake has fallen 12.8 points since December 2023. The company has had an auditor change, a director resignation and two CS changes in about 12 months.

  3. Earnings dependence on treasury income. Other income was 37.5% of FY2026 pre-tax income and 60% of Q1 FY27 pre-tax income. Operating margin swings from 3.5% to 15.0% quarter to quarter, which makes earnings unreliable.

Concluding analyst verdict.

B2B Software Technologies is a debt-free micro-cap Microsoft Dynamics specialist with a small but real proprietary IP layer. Its financial profile is conservative and its capital efficiency is poor. Over FY2021–FY2026 it compounded revenue at about 15% a year to INR 30.46 Cr, grew net income at about 9% a year to INR 2.84 Cr, and accumulated an INR 18 Cr investment book. That book now underwrites about half its market value. Stripped of treasury assets, the operating business trades at roughly 7x EBITDA while earning about 25% on operating capital. On paper that is undemanding.

The dossier, however, surfaces three issues that keep the discount rational rather than anomalous. First, recent growth is concentrated in a low-margin US subsidiary. The flagship AI contract that underpins the "Emerging Technologies" narrative is a shareholder-approved related-party transaction, not an arm's-length market validation. Second, profitability has not scaled. Operating margins in FY2026 (8.3%) remain about half the FY2022 peak, and other income still props up a third or more of pre-tax profit. Third, governance signals are mixed. Steady promoter selling, an auditor change, a director exit and rapid Company Secretary turnover have occurred alongside shareholder-friendly corporate actions (bonus, first dividend) whose market impact has already faded: the stock is down about 31% over six months.

The investment case therefore hinges less on the AI pivot than on two verifiable developments. The first is whether the company can win non-related Emerging Technologies or Business Central mandates, as the June 2026 East Africa order hints, at margins above 10%. The second is whether the board deploys or distributes its surplus capital. Absent both, the stock is likely to remain a low-liquidity value trap. With both, the re-rating potential is meaningful.

Q2 FY27 margin quality and related-party revenue mix are the next decisive data points.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / appointmentBackgroundAgeSource

Dr. Ramachandra Rao Nemani

Chief Executive Officer (KMP)

Since 23 August 2014 per MarketScreener; co-built the business from 2000

Medical doctor (MD); director of B2B Softech Inc., Exotic Granite & Marble Inc. and former Singapore, Malaysia and German group entities

—

Yahoo Finance; MarketScreener; MarketsMojo

Mr. Bala Subramanyam Vanapalli

Whole-time / Executive Director

Director since 1 October 2014; re-appointed at the 32nd AGM (28 August 2026)

Signs Regulation 30 disclosures; holds ESOP grants

Born 1970 (about 56)

Zauba; Yahoo; ScanX

Mr. Sunil Nemani

Chief Financial Officer (KMP)

———

Yahoo Finance

Dr. Avinash Yaramati (DIN 09804102)

Non-Executive, Non-Independent Director

Additional Director 12 July 2025; regularised 29 September 2025; re-appointed (retire-by-rotation) 28 August 2026

MS (General Surgery), Mamata Medical College; MBBS, Mahatma Gandhi Medical College & Research Institute; Registrar in Surgical Gastroenterology at Star Hospitals, Hyderabad; academic roles at NIMS and other medical colleges

—

FY2025 Directors' Report; ScanX

Mr. Suresh Chode (DIN 03473921)

—

Since 30 September 2019

——

Zauba

Ms. Rajeswari Immani (DIN 07127791)

Director

Since 30 September 2015

——

Zauba

Mr. Yarava Hari Prasad

Manager, Finance & Accounts

———

Yahoo

Mr. Kolli Satish

Technical Head

———

Yahoo

Company Secretary

Vacant or unconfirmed. Ms. Yamini Saini was appointed 22 April 2026; a CS resignation took effect 17 July 2026

—

Ms. Saini: qualified CS with more than 7 years' experience

—

ScanX

“—” = not publicly disclosed.

Directors' Remuneration

ExecutiveSalaryBonusStock (ESOP)TotalYear / source

Bala Subramanyam Vanapalli

—

Performance bonus approved at the AGMs of September 2025 and August 2026 (amounts not disclosed)

24,811 options granted November 2025

INR 5.77 million (reported "pay")

Yahoo Finance (fiscal year not specified, likely FY2025)

Non-executive directors

Sitting fees (amounts not disclosed)

————

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

12 Jul 2025

Yaramati Satyanarayana ceased as Chairman and Non-Executive Director; Dr. Avinash Yaramati appointed Additional Director

Promoter-family succession is likely given the shared surname, but the relationship is not disclosed

26 Aug 2025

Woman director's resignation effective

Board approved 12 August 2025

29 Sep 2025

Statutory auditor changed to M. V. Vijaya Kumar & Co.

Also appointed DSMR & Associates as secretarial auditor

22 Apr 2026

Yamini Saini appointed CS and Compliance Officer

—

17 Jul 2026

CS resignation effective

Second Company Secretary transition within about three months

28 Aug 2026

Dr. Yaramati Avinash and Mr. Vanapalli re-appointed

All AGM resolutions passed with more than 99.7% public non-institutional approval

Shareholding Trend

Holder categorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Promoter & promoter group (%)

60.0559.8359.8362.6662.4659.6359.5956.5356.53

Public (%)

34.7634.9834.9936.6336.8435.1837.4740.5242.46

Others, incl. ESOP trust (%)

5.185.185.180.700.705.182.932.931.00

Foreign institutional investors (%)

000000000

Domestic institutional investors (%)

000000000

Number of shareholders

8,3508,1658,1378,0118,0317,8608,5049,0339,017

Major Shareholders

HolderStake (%)SharesNote

Ravileela Granites Limited

13.041,511,000

Corporate holder (promoter-group affiliation likely; Dr. Nemani is a director of Exotic Granite & Marble Inc.)

Srinivas Reddy Parvatha Reddy

1.83212,410

Individual

J. Vasantha Reddy

0.6069,954

Individual

Harshini

0.1618,000

Individual

Samantha Reddy

0.1415,900

Co-founder

Neelam Jayanth Reddy

0.077,900

Individual

Competitive Landscape

Competitors by Segment

SegmentNamed competitorsPositioning vs. B2B Software

Microsoft Dynamics implementation (India and global)

Sonata Software (Microsoft partner of more than 30 years; member of the Microsoft Inner Circle); Kellton Tech Solutions (Hyderabad; ERP and digital transformation); Hitachi Solutions; Cognizant, Infosys and TCS Dynamics practices; numerous private Indian Dynamics partners

B2B is a niche, sub-scale player without any Inner Circle status of the kind Sonata cites

ERP products (India-origin)

Ramco Systems (own ERP, payroll and aviation suites)

Ramco is a full-stack ERP vendor; B2B sells add-ons on Microsoft's platform

Hyderabad small-cap IT services

Tera Software; Kellton Tech; TechNVision Ventures; Blue Cloud Softech Solutions

Comparable listing tier; most are larger and faster-growing

ERP alternatives (platform competitors)

Oracle (NetSuite), SAP Business One, Fujitsu (PitchBook lists Fujitsu, Biprogy, Fujitsu Frontech North America and Oracle as competitors)

Platform-level competition affecting Dynamics share

US physician practice management / EMR

Large US EHR and practice-management vendors (Epic, Oracle Health, athenahealth, eClinicalWorks are the industry's major names; no head-to-head data available)

GeniusDoc is a niche product with minimal disclosed scale

AI / emerging technologies services

Every Indian IT services firm, from Tier-1 to micro-cap (e.g. Sonata, Saksoft, Happiest Minds)

B2B is a new entrant with one anchor (related-party) client

Peer Comparison FY2026

MetricB2B SoftwareSonata SoftwareKellton TechRamco SystemsTera Software

Revenue (INR Cr)

30.4610,701.21,216.94700.95238.05

Revenue growth YoY (%)

26.25.410.918.5121.9

Operating / EBITDA margin (%)

8.36.911.822.615.4

Net income (INR Cr)

2.84464.491.6741.8424.80

Net margin (%)

9.34.37.56.010.4

Company Snapshot

$3.5M

Revenue

106

Employees

1994

Founded

Hyderabad, India

Headquarters

SWOT Analysis

Strengths

  • Zero debt for 12 consecutive years. Borrowings were INR 0.00 Cr at every year-end from FY2015 to FY2026, and finance cost has been zero (Screener).
  • Large liquid cushion. INR 18.01 Cr of investments at FY2026 equals about 48% of market capitalisation and 59% of annual revenue.
  • Accelerating top line. Revenue grew 18.8% in FY2025 and 26.2% in FY2026. The 5-year revenue CAGR is 15.4% (FY2021–FY2026).
  • Improving cash generation. FY2026 operating cash flow was INR 3.31 Cr and free cash flow INR 3.13 Cr (110% of net income), both record highs.
  • Collection discipline. Debtor days fell from 33.4 in FY2024 to 13.1 in FY2026.
  • Proprietary certified IP. Five named add-on modules plus GeniusDoc create recurring licence and AMC streams; licences were bundled in the June 2026 Learnovate order.
  • Shareholder-friendly turn. The first dividend (40.8% payout in FY2026), a 1:2 bonus, and approval rates above 99.9% on postal ballots.

Weaknesses

  • Sub-scale. Revenue of INR 30.46 Cr and about 106 employees are too small to bid for enterprise programmes.
  • Low core margin. Operating margin excluding other income averaged 9.6% over FY2022–FY2026 and was only 3.48% in Q4 FY26.
  • Earnings quality. Other income contributed 37.5% of FY2026 pre-tax income and 60% of Q1 FY27 pre-tax income.
  • Margin-dilutive growth engine. The implied US-subsidiary net margin was about 3.8% in FY2026, versus about 14.3% at the parent.
  • No disclosure infrastructure. There are no earnings calls, guidance, investor presentations or segment profit disclosure.
  • Governance-function churn. Two Company Secretary transitions between April and July 2026; a statutory auditor change in September 2025; a director resignation in August 2025.
  • Legacy platform exposure. The add-ons were built on NAV and AX, both superseded by Microsoft.

Opportunities

  • NAV/AX to Business Central/D365 migration of the existing customer base. The June 2026 Business Central order demonstrates current-platform capability.
  • AI on Dynamics and in healthcare. The USD 1 million oncology AI contract gives a reference case for selling to non-related US practices.
  • East Africa expansion through the Learnovate channel (Kenya and Ethiopia).
  • Capital deployment. INR 18 Cr of investments could fund acquisitions, product development or higher payouts.
  • Liquidity improvement. The proposed 1:5 split, if executed, would lower the per-share price and could widen retail participation, which is already up from 6,971 to 9,017 shareholders between March 2024 and September 2026.
  • The RSU scheme could improve retention in a tight AI talent market.

Threats

  • Related-party concentration. The largest disclosed order (USD 1 million) is a shareholder-approved material related-party transaction with Antelope Valley Cancer Center.
  • Promoter sell-down. Holding fell from 69.36% (December 2023) to 56.53% (September 2026).
  • Microsoft partner-program changes. The "Gold" designation the company still cites was retired by Microsoft in 2022.
  • Wage inflation outpacing pricing. Employee cost CAGR was 15.3% over FY2022–FY2026, against a revenue CAGR of 11.2% over the same period.
  • Share-price de-rating. The stock fell 30.6% in six months to October 2026 (ScanX), raising the cost of equity for any future issuance.
  • Competition from scaled Microsoft partners. Sonata Software has about 350 times B2B's revenue and Inner Circle status.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19 May 2025250,325 ESOP options granted to employeesRetention tool; about 2.2% of the pre-bonus base
20 May 2025FY2025 results: revenue INR 24.14 Cr (+18.8%), net income INR 2.63 Cr (+42.2%); Q4 FY25 revenue INR 7.48 Cr (+19.5%)Growth re-acceleration confirmed
Jun 2025 quarterShareholding "Others" drops to 0.70% from 5.18%Possible ESOP-trust movement (reversed by December 2025)
12 Jul 2025Chairman Yaramati Satyanarayana exits; Dr. Avinash Yaramati joins as Additional DirectorBoard succession
Aug 2025Q1 FY26 results: revenue INR 6.47 Cr, net income INR 0.65 CrMargin trough (operating margin 4.3%)
12 Aug 2025Board accepts a woman director's resignation (effective 26 August)Board composition risk
13 Aug 2025USD 1 million (about INR 8.65 Cr) five-year AI order from Antelope Valley Cancer Center; stock rises about 6% intraday to INR 32.68Largest disclosed order; related party
14 Aug 2025Emerging Technologies division announced with INR 1 Cr capexStrategic repositioning
Sep 2025Emerging Technologies division begins operationsExecution start
29 Sep 202531st AGM: new statutory and secretarial auditors, related-party approval, Executive Director bonus and ESOP termsGovernance reset
4 Nov 2025Q2 FY26: revenue INR 7.66 Cr (+23.2%), net income INR 0.63 Cr (+103%); 1:5 split and RSU scheme proposed; 24,811 options to Executive DirectorStrong quarter; corporate-action signals
16 Jan 2026Stock closes at INR 24.85, down 21.3% over 12 months (pre-bonus)Sentiment low point
30 Jan 2026Q3 FY26: consolidated revenue INR 8.28 Cr (+53% year-on-year), net income INR 1.24 Cr; standalone net income INR 1.10 Cr (+85%); 1:2 bonus and INR 1 interim dividend approvedBest quarter in company history; first dividend
6–7 Feb 2026Dividend record dateCapital return begins
9 Feb 202652-week high of INR 38.00 recordedPost-announcement spike (pre- or post-bonus adjustment basis unclear)
16–18 Mar 2026Postal ballot approves the bonus and authorised capital of INR 18 Cr (99.9992% for)Shareholder endorsement
27–31 Mar 2026Bonus record date fixed at 2 April 2026—
6 Apr 20265,792,700 bonus shares allotted; trading from 7 AprilShare count rises to 17.38 million
11 Apr 2026FY2026 results: revenue INR 30.46 Cr (+26.2%), net income INR 2.84 Cr (+8.0%); Q4 FY26 net income INR 0.32 Cr (–42.9% year-on-year); internal auditor appointedWeak Q4 margin (3.5%)
22 Apr 2026Yamini Saini appointed CS—
27 Apr 2026FY2025-26 disclosure that the company is not a "large corporate" (SEBI debt-market framework)Confirms no significant borrowings
2–3 Jun 2026USD 162,754 Learnovate / Kongoni River Farm order (Kenya and Ethiopia); stock rises 4.6% to INR 24.44Geographic diversification
9 Jul 2026CS resignation accepted, effective 17 JulyCompliance-function churn
17–18 Jul 2026Q1 FY27: revenue INR 7.39 Cr (+14.2%), net income INR 0.92 Cr (+41.5%); other income INR 0.73 CrProfit growth driven partly by other income
6 Aug 202632nd AGM notice published—
28 Aug 202632nd AGM: all five resolutions passed; directors re-appointed; auditor extension; Executive Director performance bonusRoutine; promoter group voted unanimously
29 Sep 2026Trading window closed for Q2 FY27Results expected around late October or November 2026
6 Oct 2026Regulation 74(5) compliance certificate filed for the September 2026 quarterRoutine
19 Oct 2026Stock closes at INR 21.40 (market cap INR 37.2 Cr); 6-month return –30.6% (ScanX)De-rating since the bonus

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 199.1 Mn in FY2022 to INR 304.6 Mn in FY2026.
B2B Software Technologies Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations199.1197.7203.2241.4304.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Screener.in — B2B Software Technologies (consolidated financials, ratios, shareholding, announcements) (screener.in)
  2. Screener.in — standalone view (screener.in)
  3. Business Standard / Capital Market — Q4 FY25 and FY25 results (business-standard.com)
  4. Business Standard / Capital Market — Q2 FY26 results (business-standard.com)
  5. Business Standard — share price and returns (January 2026) (business-standard.com)
  6. JM Financial / Capital Market — Q1 FY27 consolidated (jmfinancialservices.in)
  7. JM Financial / Capital Market — Q1 FY27 standalone (jmfinancialservices.in)
  8. Equitybulls — Q1 FY27 detail (equitybulls.com)
  9. KotakNeo — Q4 FY26 summary (kotakneo.com)
  10. Anand Rathi — annual results feed (anandrathi.com)
  11. Research360 — expense breakdown (beta.research360.in)
  12. Bajaj Broking — standalone quarterly and annual (bajajbroking.in)
  13. GoodReturns — FY2025 Directors' Report excerpts (goodreturns.in)
  14. ScanX — company newsflow (scanx.trade)
  15. ScanX — 31st AGM outcomes and Emerging Technologies division (scanx.trade)
  16. ScanX — Q3 FY26, bonus and dividend (scanx.trade)
  17. ScanX — bonus record date (scanx.trade)
  18. ScanX — Learnovate order (scanx.trade)
  19. InvestmentGuruIndia / Accord Fintech — Antelope Valley order (investmentguruindia.com)
  20. InvestmentGuruIndia / Accord Fintech — Learnovate order (investmentguruindia.com)
  21. Chola Securities / Capital Market — bonus record date (cholasecurities.com)
  22. Trendlyne — corporate actions (trendlyne.com)
  23. Trendlyne — shareholding (March 2024) (trendlyne.com)
  24. Nirmal Bang — company profile (nirmalbang.com)
  25. ZaubaCorp — MCA director data (zaubacorp.com)
  26. Kompass — registration and address (de.kompass.com)
  27. Yahoo Finance — profile and key executives (sg.finance.yahoo.com)
  28. MarketScreener — Dr. R. R. Nemani (ch.marketscreener.com)
  29. MarketScreener / Zonebourse — P. Samantha Reddy (ch.zonebourse.com)
  30. MarketsMojo — company CV (marketsmojo.motilaloswal.com)
  31. EMIS — company profile (emis.com)
  32. PitchBook — profile (pitchbook.com)
  33. Simply Wall St — profile (simplywall.st)
  34. Groww — 32nd AGM summary (groww.in)
  35. mibuso — 2009 business directory (mibuso.com)
  36. Company website (investors / annual reports) · b2bsoftech.com
  37. Sonata Software — Q4 FY26 press release (sonata-software.com)
  38. Sonata Software — FY26 summary (FilingReader) (filingreader.com)
  39. Ramco Systems — FY26 results (Arihant / Capital Market) (arihantcapital.com)
  40. Kellton Tech — FY26 results (Anand Rathi) (anandrathi.com)
  41. Kellton Tech — FY26 results (ScanX) (scanx.trade)
  42. Tera Software — FY26 results (Arihant / Capital Market) (arihantcapital.com)
  43. MarketScale / Circana — US B2B technology spending H1 2026 (marketscale.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.